Cargando…
Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms
BACKGROUND: Dual checkpoint inhibitor therapy with anti-programmed cell death protein 1 and anti-cytotoxic T-lymphocyte-associated protein 4 therapy has shown promising results in patients with high-grade neuroendocrine neoplasms (NENs), demonstrating varying response rates of 9%-44%. More data are...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728436/ https://www.ncbi.nlm.nih.gov/pubmed/34973511 http://dx.doi.org/10.1016/j.esmoop.2021.100364 |